Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea

Author

Han S, Kim S, Kim H, and Suh HS

Journal

Current Medical Research and Opinion

Volume(Issue)

35(9)

Page

1597-1605

Publication Date

2019.09.